Guizhou Bailing Group Pharmaceutical (SHE:002424) subsidiary Baili Yuxiu (Zhuhai) Pharmaceutical received clinical trial approval for its self-developed BD77 for inhalation, according to a Tuesday filing with the Shenzhen bourse.
The drug is indicated for patients with chronic obstructive pulmonary disease, the filing said.